Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Recruiting
Observational Study
Baseline Thrombocytopenia
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Methodist Health System · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ≥ 18 years
* PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
* Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
* At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ti…
Contacts